Skip to main content
. Author manuscript; available in PMC: 2017 Mar 15.
Published in final edited form as: Cancer. 2015 Dec 28;122(6):935–945. doi: 10.1002/cncr.29848

Table 1.

Clinical and pathology/biology features of 7,102 patients with neuroblastoma according to MYCN amplification status.

Clinical features Sample size (N)1 All
(%)		 MYCN Non-amplified
(%)2 		MYCN Amplified
(%)2 		P-value3 Odds
Ratio4
Mean age at diagnosis,
months		 7102 25.1 24.3 28.1 <0.001 N/A
Age at diagnosis 7102 <0.001 3.0
    ≥ 18 months 42.8 75.3 24.7
    < 18 months 57.2 90.1 9.9
INSS Stage 7003 <0.001 5.1
    4 36.9 69.6 30.4
    Not Stage 4 63.1 92.1 7.9
INSS Stage 7003 <0.001 N/A
    1 23.9 97.1 2.9
    2 14.1 96.0 4.0
    3 17.6 82.4 17.6
    4S 7.5 91.1 8.9
    4 36.9 69.6 30.4
Primary tumor site 6815 <0.001 2.5
    Adrenal5 45.9 77.1 22.9
    Non-Adrenal 54.1 89.2 10.8
Primary tumor site 6815 <0.001 7.1
    Non-Thoracic 84.7 81.2 18.8
    Thoracic5 15.3 96.9 3.1
Lactate dehydrogenase (U/L) 4354 <0.001 8.4
    ≥ 587 48.6 70.9 29.1
    < 587 51.4 95.3 4.7
Serum ferritin (ng/mL) 3602 <0.001 4.2
    ≥ 92 48.8 74.0 26.0
    < 92 51.2 92.2 7.8
Pathology/Biology features
International Neuroblastoma
Pathology Classification		 3866 <0.001 14.8
    Unfavorable 35.0 66.7 33.3
    Favorable 65.0 96.7 3.3
Ploidy 3516 <0.001 3.9
    ≤ 1 (diploid, hypodiploid) 29.2 71.2 28.8
    > 1 (hyperdiploid) 70.8 90.5 9.5
Tumor diagnosis7 3349 <0.001 10.1
    Neuroblastoma or
ganglioneuroblastoma,
nodular		 95.3 83.6 16.4
    Ganglioneuroblastoma (except
nodular) or ganglioneuroma
(maturing subtype)		 4.7 98.1 1.9
Tumor diagnosis (N=3349) 7 3349 <0.001 9.3
    Neuroblastoma 89.1 82.7 17.3
    Ganglioneuroblastoma or
ganglioneuroma (maturing subtype)		 10.9 97.8 2.2
Grade of differentiation 2871 <0.001 4.6
    Undifferentiated/Poorly
differentiated		 83.8 82.1 17.9
    Differentiating 16.2 95.5 4.5
MKI 2738 <0.001 16.8
    High 11.8 39.6 60.4
    Low/Intermediate 88.2 91.7 8.3
LOH at 1p 2026 <0.001 19.8
    Present 22.2 46.3 53.7
    Absent 77.8 94.5 5.5
Pooled segmental chromosomal
aberration 6 		2060 <0.001 10.4
    Present 31.7 61.5 38.5
    Absent 68.3 94.3 5.7
Aberration at 11q 1033 0.001 0.4
    Present 20.9 91.7 8.3
    Absent 79.1 82.1 17.9
Gain of 17q 340 0.01 2.1
    Present 47.7 73.5 26.5
    Absent 52.3 84.8 15.2
1

N represents total with known data for the given variable.

2

Row percentages sum to 100%.

3

P-value refers to a student’s T-test (for continuous age variable) or a chi-squared test for all other variables.

4

Odds ratio for univariate logistic regression with MYCN amplification as dependent variable.

5

Primary tumor site [adrenal or thoracic] versus all other primary tumor sites.

6

LOH at 1p, gain of 17q, and/or aberration at 11q.

7

International Neuroblastoma Pathology Classification tumor diagnosis category (includes neuroblastoma, ganglioneuroblastoma intermixed, ganglioneuroma maturing subtype or ganglioneuroblastoma well differentiated, ganglioneuroblastoma nodular, or unknown).